Fig. 2: Mucins investigated in precursor lesions and lower GIT adenocarcinomas.

a, b Upset plots visualizing mucin distribution in benign precursor lesions (a) and malignant tumours (b). Each bar above the matrix represents the number of studies that examined a specific mucin signature. c, d Mucin network charts for benign precursor lesions (c) and malignant tumours (d). The number between brackets indicates how many times a mucin was investigated in the included studies and represents the thickness of the dots. The thickness of each line represents how often mucins were co-examined. e, f Sankey chart visualizing the distribution of mucins across the various types of precancerous lesions (adenomatous and serrated polyps) (e) and adenocarcinomas (colorectal cancer (CRC), small intestinal adenocarcinoma (SIA) and rare tumours) (f). The width of each flow indicates how frequently a mucin is investigated in a (pre)malignant lesion type and the number between brackets indicates the number of studies investigating a mucin in a (pre)malignant lesion type.